Metraipolis › archive › dc_ddeca60dec0d

SGLT2 Inhibitor and GLP-1 Receptor Agonist Prescriptions in Newly Diagnosed Type 2 Diabetes Patients With Cardiorenal Risks: A Cross-Sectional Study — Europe PMC PMID:41220901

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41220901
DOI: 10.1155/jdr/6656982
License (as archived): solo-consultazione
Archived: 2026-11-08T20:07:01.715Z
SHA-256 of the archived text: fd80d1bbfdbb1a80b60599597c3a5b57b6ebf243e381c82f3f12faaab4fe1d46
Stable URL of this page: https://metraipolis.com/documento/dc_ddeca60dec0d

How to cite

SGLT2 Inhibitor and GLP-1 Receptor Agonist Prescriptions in Newly Diagnosed Type 2 Diabetes Patients With Cardiorenal Risks: A Cross-Sectional Study — Europe PMC PMID:41220901 — Europe PMC (en), https://europepmc.org/article/MED/41220901 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ddeca60dec0d (Metraipolis archive dc_ddeca60dec0d, sha256 fd80d1bbfdbb1a80b60599597c3a5b57b6ebf243e381c82f3f12faaab4fe1d46)

BibTeX

@misc{dcddeca60dec0d,
  title = {SGLT2 Inhibitor and GLP-1 Receptor Agonist Prescriptions in Newly Diagnosed Type 2 Diabetes Patients With Cardiorenal Risks: A Cross-Sectional Study — Europe PMC PMID:41220901},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41220901},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ddeca60dec0d; sha256 fd80d1bbfdbb1a80b60599597c3a5b57b6ebf243e381c82f3f12faaab4fe1d46},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41220901. Agents can read the archived copy with the MCP tool read_document.